期刊
GASTROENTEROLOGY
卷 154, 期 2, 页码 421-436出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2017.07.041
关键词
Barrett's Esophagus; Esophageal Cancer; Screening; Endoscopy
资金
- C2 Therapeutics
- Cook Medical
- Pentax
- Cosmo Pharmaceuticals
- Medical Research Council [MC_UU_12022/2] Funding Source: researchfish
- MRC [MC_UU_12022/2] Funding Source: UKRI
Because the esophagus is easily accessible with endoscopy, early diagnosis and curative treatment of esophageal cancer is possible. However, diagnosis is often delayed because symptoms are not specific during early stages of tumor development. The onset of dysphagia is associated with advanced disease, which has a survival at 5 years lower than 15%. Population screening by endoscopy is not cost-effective, but a number of alternative imaging and cell analysis technologies are under investigation. The ideal screening test should be inexpensive, well tolerated, and applicable to primary care. Over the past 10 years, significant progress has been made in endoscopic diagnosis and treatment of dysplasia (squamous and Barrett's), and early esophageal cancer using resection and ablation technologies supported by evidence from randomized controlled trials. We review the state-of-the-art technologies for early diagnosis and minimally invasive treatment, which together could reduce the burden of disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据